- Sunesis Pharmaceuticals (SNSS -0.9%) announces that it has submitted its responses to the European Medicines Agency's Day 180 List of Outstanding Issues generated by the Committee for Medicinal Products for Human Use (CHMP) regarding its marketing application seeking approval of vosaroxin for the treatment of relapsed/refractory acute myeloid leukemia (AML). The responses and clinical data will be review by the advisory group's Oncology Division next month.
- The company says it is in the process of recruiting a commercialization partner for an expected H2 launch in Europe.
- Vasoroxin, branded as QINPREZO, is an anti-cancer quinolone derivative, a class of compounds (antibiotics) not previously used to treat cancer. It inhibits an enzyme called topoisomerase II which results in site-selective DNA damage and cancer cell death.